-
Mashup Score: 0Primary Bladder Sarcoma: A Multi-Institutional Experience From the Rare Cancer Network - Beyond the Abstract - 22 hour(s) ago
bladder cancer, Bladder Sarcoma, sarcoma of the urinary bladder (SUB), Retroperitoneal sarcomas (RPS), Rare Cancer Network, primary sarcoma of the urinary bladder, urothelial carcinoma (UC) of the bladder.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0Multiple Opinions Are ‘Crucial’ for Muscle-Invasive Bladder Cancer - 23 hour(s) ago
Quality of life, sexual outcomes and self-image should be considered before choosing a treatment option for muscle-invasive bladder cancer, an expert said.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 0Advanced Wound Healing Techniques Shorten Healing Time in Bladder Cancer - Oncology Nurse Advisor - 4 day(s) ago
A cross-sectional study compared advanced wound techniques with traditional suturing in patients who have undergone surgical treatment for bladder cancer.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Empowering Bladder Cancer Care: A Formal Partnership between IBCG and UroToday in the Era of Expanding Therapies - 5 day(s) ago
The International Bladder Cancer Group (IBCG) and UroToday, optimizing bladder cancer patient care, AUA-IBCG Bladder Cancer Forum, bladder cancer education, enfortumab vedotin-ejfv in combination with pembrolizumab.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 21First-in-human trial finds new bladder cancer treatment safe - 5 day(s) ago
A first-in-human trial led by The University of Western Australia has found injecting an immunotherapy drug directly into the bladder wall to treat cancer is viable and safe.
Source: medicalxpress.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 21FDA Approves First-line Nivolumab Combo for Urothelial Carcinoma - 12 day(s) ago
Results from the phase 3 CHECKMATE-901 trial led to the approval of nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 6The EV-302 Study and the Implications for Metastatic Bladder Cancer Care - Cora Sternberg - 14 day(s) ago
Alicia Morgans speaks with Cora Sternberg about the EV-302 study presented at ESMO 2023. This study marks a significant shift in treating advanced metastatic urothelial cancer, traditionally managed with cisplatin or carboplatin-based chemotherapy. EV-302 introduces a combination of enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, and pembrolizumab, an anti-PD-1 inhibitor…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The EV-302 study and implications for metastatic #BladderCancer care. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship @DanaFarber to discuss a possible new standard of care for metastatic urothelial cancer, significantly improving patient outcomes > https://t.co/shpMxDA8FO https://t.co/LHcSFJqyfl
-
-
Mashup Score: 19Petros Grivas – Championing Academic Partnership, Mentorship in UC | GU Oncology Now - 14 day(s) ago
Dr. Grivas shares insights into his career trajectory, driven by a passion to revolutionize the care of patients with UC.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 13New Research Sheds Light on Alternative Treatments for Node-Positive Bladder Cancer - Martin Swinton - 15 day(s) ago
Leslie Ballas engages with Martin Swinton on his publication about bladder-sparing treatment options for clinically node-positive nonmetastatic bladder cancer. The study compares the efficacy of bladder-sparing treatment using radical dose radiotherapy to traditional radical cystectomy and finds no significant difference in overall survival rates. This supports bladder preservation as a viable…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 5The Patient's Guide to Understanding New Agents for Non-Muscle Invasive Bladder Cancer - Guru Sonpavde - 19 day(s) ago
Guru Sonpavde provides a comprehensive overview of emerging agents for non-muscle invasive bladder cancer, highlighting both successes and challenges. He discusses a small phase one trial of intravesical pembrolizumab, noting its biological activity but also raising concerns about systemic immune adverse events. Dr. Sonpavde also mentions the recently approved nadofaragene (Adstiladrin), an…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
Exploring primary sarcoma of the urinary bladder, an uncommon and aggressive type of #BladderCancer. Insights from a multi-institutional study highlight the need for personalized treatments, emphasizing the importance of optimizing local therapies > https://t.co/bSyms3vlm1 https://t.co/XA7XYPk8UK